Organon (OGN) Liabilities from Discontinued Operations (2020 - 2025)
Organon (OGN) posted quarterly Liabilities from Discontinued Operations of 32000000.0 for Q4 2025, down 27.27% on a QoQ basis from 44000000.0 in Q1 2021.
Organon (OGN) Liabilities from Discontinued Operations (2020 - 2025) Analysis & Trends
Organon (OGN) has reported Liabilities from Discontinued Operations for 3 consecutive years, with 32000000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 32000000.0; the TTM figure through Dec 2025 stood at 32000000.0 (changed N/A YoY), while the FY2025 annual figure was 32000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations came in at 32000000.0 for Q4 2025 at Organon, down from 44000000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 44000000.0 in Q1 2021, with the low at 32000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.00 Mn |
| Dec 31, 2025 | 32.00 Mn |
| Mar 31, 2021 | 44.00 Mn |
| Mar 31, 2021 | 44.00 Mn |
| Dec 31, 2020 | 83.00 Mn |
| Dec 31, 2020 | 83.00 Mn |